Thomas Wadden explains the rationale behind STEP 3 trial, and why semaglutide is the “breakthrough people with overweight and obesity have been waiting for.” (7:41)
Add-on treatment with subcutaneous semaglutide 2.4 mg produces a marked increase in weight loss for people without diabetes undertaking an intensive lifestyle intervention to combat obesity, report the STEP 3 investigators in JAMA.